Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

The dangerous risks of stopping Ozempic and GLP-1s (opens in a new tab)

axios.com · 2026-09-21

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

3 key claims are not backed by the study.

  • 2 supported
  • 2 overstated
  • 3 not supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Five claims go beyond the study. Two overstate it and three aren't supported at all.

  • 2 supported
  • 2 overstated
  • 3 not supported
Open claim evidence
3
Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not supportedAn August JAMA Network Open study of more than 157,000 first-time semaglutide users taking it for obesity in Denmark found that 49% discontinued the drug within 12 months, and about one-quarter of those who stopped restarted within three months.View evidenceHide evidence

As stated49% discontinued within 12 months; about one-quarter restarted within three months

Why this verdict

The supplied paper profile is not the Danish semaglutide-obesity discontinuation study and does not report 157,000 Danish first-time semaglutide users, 49% discontinuation within 12 months, or restart rates. These details are outside the supplied paper evidence.

Claim 2 of 7Not supportedA review published in March in Diabetes, Obesity and Metabolism found that stopping GLP-1 treatment within the first year was associated with higher risks of coronary artery disease and heart failure compared with continued treatment, and that 60%–90% of lost weight may return within a year.View evidenceHide evidence

As stated60%–90% of lost weight may return within a year

Why this verdict

The supplied profile is not a March Diabetes, Obesity and Metabolism review and does not report coronary artery disease or heart failure outcomes, nor 60%–90% weight regain within a year. The VA paper reports MACE associations, not these review findings.

Claim 3 of 7Not supportedA recent Cell Reports study in mice suggests there could be a biological mechanism, described as an 'obesity memory' in fat cells, that may help explain why the body is prone to regain weight after weight loss.View evidenceHide evidence

Why this verdict

The supplied paper profile contains no mouse study, Cell Reports evidence, fat-cell mechanism, or 'obesity memory' finding. This claim is outside the supplied paper evidence.

Claim 4 of 7OverstatedEmerging research suggests some cardiovascular and metabolic benefits of GLP-1 treatment can fade after treatment ends.View evidenceHide evidence

Why this verdict

The cardiovascular portion is supported: continuous GLP-1RA use was associated with greater cardiovascular benefit, and discontinuation/interruption was associated with higher MACE risk versus continued use. However, the supplied paper profile does not report metabolic outcomes such as blood sugar, lipids, blood pressure, or weight regain, so the claim extends beyond the abstract-level evidence by adding metabolic benefits.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Claim 5 of 7OverstatedA review published in Nature Reviews Endocrinology in May found that stopping GLP-1s commonly leads to rising blood sugar and loss of improvements in cardiovascular risk factors, and warned that stopping and restarting could increase long-term heart risks due to fluctuations in weight and blood sugar.View evidenceHide evidence

Why this verdict

The supplied paper supports part of the claim insofar as discontinuation and interruption of GLP-1RA use were associated with higher 3-year MACE risk versus continued use. However, the profile does not report rising blood sugar, loss of cardiovascular risk-factor improvements, or a Nature Reviews Endocrinology review. The metabolic and fluctuation-mechanism portions therefore exceed the supplied evidence.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Claim 6 of 7SupportedStopping Ozempic and other GLP-1 drugs may carry health risks beyond weight regain.View evidenceHide evidence

Why this verdict

At abstract depth, the paper supports a hedged, associational version of this headline: among VA patients with type 2 diabetes who initiated GLP-1RAs, discontinuation or interruption was associated with higher 3-year MACE risk compared with continued GLP-1RA use. The headline is broad, but it does not claim causality and is consistent with the paper’s cardiovascular-outcome evidence beyond weight regain.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Claim 7 of 7SupportedA Washington University School of Medicine study found that stopping GLP-1 treatment was associated with a rapid increase in cardiovascular risk.View evidenceHide evidence

As stated22% higher relative risk of heart attack, stroke and death after two years without GLP-1 treatment

Why this verdict

The main cardiovascular-risk claim and stated magnitude are supported by the paper profile: discontinuing GLP-1RA for 2 years versus continued use was associated with higher 3-year MACE risk, IRR 1.22, for a composite of myocardial infarction, stroke, or all-cause death. The abstract-level profile does not substantiate the quoted mechanistic/risk-factor language about inflammation, blood pressure, and cholesterol, but the core association and 22% relative increase match the profile.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The study population was VA users with type 2 diabetes who initiated GLP-1RAs, with a sulfonylurea initiator comparator for one main analysis.

    The story presentation broadly refers to Ozempic/GLP-1 users and notes that many patients have diabetes or obesity, but it does not clearly reflect that this paper’s cohort was specifically VA patients with type 2 diabetes or that one main comparison used sulfonylurea initiators as the reference group. This matters for generalizability and interpretation.

    From Target trial emulation; incident-user cohort assembly; time-varying exposure operationalisation; Target trial emulation

  • The abstract does not provide detailed confounding-control methods, time-varying confounding handling, exposure gap algorithms, or full generalizability information.

    The story mentions observational context and that underlying diabetes/obesity raise risk, but it does not reflect the abstract-level limitations about unreported adjustment/modeling details, exposure ascertainment algorithms, or limits to generalizability from the VA cohort.

    From Target trial emulation; incident-user cohort assembly; time-varying exposure operationalisation; Target trial emulation

5 things the story did carry across
  • The paper’s main evidence is an observational target-trial emulation using Veterans Affairs electronic healthcare data, not a randomized discontinuation trial.
  • The primary clinical outcome in the supplied paper was 3-year cumulative incidence of MACE, defined as myocardial infarction, stroke, or all-cause death.
  • Continuous GLP-1RA use for the full 3-year follow-up had the greatest risk reduction versus sulfonylureas, while shorter durations before discontinuation showed less or no clear benefit.
  • Within GLP-1RA initiators, discontinuation for longer durations was associated with progressively higher MACE risk versus continued GLP-1RA use: 0.5 years IRR 1.04, 1 year IRR 1.14, and 2 years IRR 1.22.
  • Interruptions of GLP-1RA use, not only permanent discontinuation, were associated with higher MACE risk versus continued use.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the association between alternative GLP-1RA treatment strategies (duration of continued use, discontinuation, interruption) versus a sulfonylurea reference strategy on 3-year risk of major adverse cardiovascular events using a target trial emulation framework.Target trial emulationExpand

In plain English

Target-trial emulation using Veterans Affairs electronic healthcare data estimated associations between prespecified GLP-1RA treatment strategies (varying durations of continued use, discontinuation, or interruption) and 3-year risk of major adverse cardiovascular events (MACE: myocardial infarction, stroke, or all-cause death), using incident sulfonylurea initiators as the reference group. Continuous GLP-1RA use for longer durations was associated with progressively lower 3-year MACE risk versus sulfonylureas; shorter durations before discontinuation showed no clear benefit. Discontinuations or interruptions of GLP-1RA use were associated with progressively higher MACE risk compared with continued use.

Key findings

  • Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)
  • GLP-1RA use for 2.0 years then discontinuation was associated with reduced 3-year MACE risk versus sulfonylureas.IRR 0.93 (95% CI 0.88 to 0.98)
“Design Target trial emulation.”
2secondary dataCharacterise real-world patterns of GLP-1RA use scenarios in VA patients with type 2 diabetes, operationalised as dynamic treatment status updates every six months and prespecified continued-use/discontinuation/interruption strategies.Target trial emulation; incident-user cohort assembly; time-varying exposure operationalisationExpand

In plain English

Constructed an incident-user cohort of Veterans Affairs (VA) patients with type 2 diabetes using the VA Corporate Data Warehouse (2017–2023) to characterise real-world GLP-1RA use patterns. Incident users of GLP-1RAs (n=132,551) and sulfonylureas (n=201,136) were identified; treatment status in the GLP-1RA arm was reassigned every six months to implement 16 prespecified strategies varying continued use, discontinuation, and interruption over a three-year follow-up.

Key findings

  • Cohort sizes of incident users were reported as GLP-1RA n=132,551 and sulfonylurea n=201,136.
  • Exposure was operationalised by reassigning treatment status every six months in the GLP-1RA arm, generating 16 prespecified strategies that varied duration of continued use, discontinuation, or interruption.
“Design Target trial emulation.”
What this piece can’t prove
  • Abstract does not report methodological details for exposure ascertainment algorithms (e.g., refill windows, permissible gaps), covariate measurement/operationalisation, or handling of missing data.

1 further detail could not be confirmed from the summary.

3secondary dataEstimate, among GLP-1RA initiators, the comparative association of discontinuation and interruption (for varying durations) versus continued GLP-1RA use with 3-year risk of major adverse cardiovascular events.Target trial emulation — dynamic post-initiation strategiesExpand

In plain English

Target-trial emulation among 132,551 US Veterans Affairs GLP-1RA initiators evaluated how varying durations of discontinuation or interruption of GLP-1RA use (vs continued GLP-1RA use) related to 3-year cumulative risk of major adverse cardiovascular events (MACE: myocardial infarction, stroke, or all-cause death). Treatment status was reassigned every six months to define 16 prespecified post-initiation strategies; risk contrasts were reported as incidence risk ratios (IRRs) over three years.

Key findings

  • Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)
  • Longer discontinuation durations were associated with progressively larger increases in 3‑year MACE risk compared with continued use.Discontinuation 1 year: IRR 1.14 (95% CI 1.09 to 1.18); discontinuation 2 years: IRR 1.22 (95% CI 1.16 to 1.27)
“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
What this piece can’t prove
  • Abstract does not specify the analytic approach used to control confounding or the exact statistical models employed for the incidence risk ratio estimates.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

GLP-1 Receptor Agonists Discontinuation and Cardiovascular Events in Type 2 Diabetes: A Population-Based Study

2026 · Crossref

Source (opens in a new tab)
Candidate

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England) · 2026 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 10 more candidates considered.